Roles
- Associate Professor of Surgery
- Co-Leader, Gastrointestinal Site Disease Group, Sylvester Comprehensive Cancer Center
- Associate Director, Translational Research, Sylvester Pancreatic Cancer Research Institute
- DiMare Family Endowed Chair in Immunotherapy
-
Biography
Dr. Datta is the DiMare Family Endowed Chair in Immunotherapy, Associate Professor of Surgery, and a hepatobiliary and pancreatic surgical oncologist at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. He is also the Associate Director of Translational Research at the Sylvester Pancreatic Cancer Research Institute, and a surgeon-scientist studying myeloid immunobiology in the pancreatic cancer microenvironment. He is also the Co-Leader of the Gastrointestinal Site Disease Group (SDG) at Sylvester where he serves as the Translational Director to augment the portfolio of investigator-initiated clinical trials offered in GI cancers.
Dr. Datta joined the faculty at the University of Miami Miller School of Medicine in 2019. He graduated Summa cum Laude from Colgate University in Hamilton, NY and attended Vanderbilt University School of Medicine in Nashville, TN where he earned his MD and was inducted in the Alpha Omega Alpha (AOA) National Honor Society. He completed his residency in General Surgery at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, during which he completed a post-doctoral research fellowship in cancer immunology in the laboratory of Brian Czerniecki. He subsequently completed a fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he focused on surgical management of hepatobiliary, pancreatic, and gastric malignancies and developed expertise in computational immunogenomics.
Since starting his lab at Sylvester, his research has been extensively funded by the Miami Clinical and Translational Science Institute with an NIH KL2 award, Stanley Glaser Foundation, American College of Surgeons’ Franklin H. Martin Research Fellowship, Association for Academic Surgery Joel J. Roslyn Faculty Award, Society for Surgical Oncology Young Investigator Award, the Elsa U. Pardee Foundation, the Pancreatic Cancer Action Network Career Development Award, and the Department of Defense Pancreatic Cancer Research Program (PCARP). -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Dr. Datta's laboratory in pancreatic cancer immunology focuses on: (1) deciphering and targeting the dominant tolerogenic myeloid cell-derived signaling mechanisms that govern T-cell dysfunction and stromal inflammation; (2) understanding how tumor-intrinsic transcriptional programs orchestrate innate immune regulation and adaptive immune dysfunction in the pancreatic tumor microenvironment; and (3) developing novel nanoengineering and tissue engineering strategies to abolish tolerogenic signaling in neutrophilic myeloid-derived suppressor cells to invigorate antitumor immune responses in pancreatic cancer.
His clinical and translational research interests are in optimizing the physiologic and biologic selection of patients for neoadjuvant therapies in GI cancer, leveraging the neoadjuvant platform to discover novel predictive biomarkers of therapeutic response and resistance, and developing novel clinical trials using combination immunotherapies for patients with localized and advanced pancreatic cancer patients. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Copyrights & Patents
Professional Activities
Articles & News
PanCAN Funds Sylvester Study of Blood Test for Pancreatic Cancer
FDA Approval Opens New Chapter in Pancreatic Cancer Treatment
How Scientists at Sylvester are Learning to Outrun Cancer Resistance
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 2 clinical trials.
-
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
- Principal Investigator: Jashodeep Datta
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Not Accepting
-
To determine if patients with persistently unresectable colorectal liver metastases (CRLM) after treatment with first-line chemotherapy have improved overall survival (OS) with Hepatic Arterial Infusion (HAI) and systemic chemotherapy versus systemic chemotherapy alone.
- Principal Investigator: Jashodeep Datta
- Study Phase: Phase III
- Enrollment Status: Open